Therapeutics Hormonal Agents

Use of menopausal hormone therapy beyond age 65 years and its effects on women's health outcomes by types, routes, and doses

Baik SH, Baye F, McDonald CJ

Published May 2024 Menopause (New York, N.Y.), 31(5), 363-371
DOI 10.1097/GME.0000000000002335 PMID 38595196 PMC PMC11465799

RRM Academy Synopsis

Estrogen alone after 65 linked to lower death risk in Medicare women

An observational cohort of 10,944,328 Medicare women found that estrogen-only therapy after age 65 was associated with a 19% lower risk of death, compared with no use or stopping. Estrogen plus a progestogen was linked to 10% to 19% more breast cancer. Results varied by hormone, route and dose.

Key Findings

  • Among 10,944,328 women in the death cohort, 14% ever used hormone therapy. Use of any estrogen-containing therapy fell from 11.4% to 5.5% between 2007 and 2020.
  • Estrogen alone was linked to 19% lower risk of death in Medicare women: 21% with estradiol, 13% with conjugated estrogen. Vaginal, transdermal and oral routes showed 30%, 20% and 11% lower risk.
  • In women aged 65 and older, estrogen alone was associated with a 16% lower breast cancer risk. Estrogen plus progestin was associated with 19% higher risk, estrogen plus progesterone 10% higher.
  • The authors saw no breast cancer increase with low-dose vaginal or transdermal estradiol plus progestin.
  • Estrogen plus progestin was associated with a 45% lower endometrial cancer risk, and estrogen plus progesterone with a 33% higher risk.

Interpretation

The study is an observational cohort analysis of Medicare claims from 2007 to 2020. Women were followed from about age 65. Hormone users differed from non-users in income, race and health conditions, and the models adjusted for these. The authors note that unmeasured factors, such as healthy habits among users, could have been present. They conclude that effects of hormone therapy after 65 vary by type, route and strength. Risk reductions appear greater with low doses, vaginal or transdermal preparations and estradiol.

RRM Context

The paper analyzes progesterone and synthetic progestins separately, and the results differ. Progesterone alone was associated with a 22% lower risk of death, and progestin alone with an 11% higher risk. RRM draws the same line between the progesterone the body makes after ovulation and synthetic progestins.

Abstract

Objectives

The study aims to assess the use of menopausal hormone therapy beyond age 65 years and its health implications by types of estrogen/progestogen, routes of administration, and dose strengths.

Methods

Using prescription drug and encounter records of 10 million senior Medicare women from 2007-2020 and Cox regression analyses adjusted for time-varying characteristics of the women, we examined the effects of different preparations of menopausal hormone therapy on all-cause mortality, five cancers, six cardiovascular diseases, and dementia.

Results

Compared with never use or discontinuation of menopausal hormone therapy after age 65 years, the use of estrogen monotherapy beyond age 65 years was associated with significant risk reductions in mortality (19% or adjusted hazards ratio, 0.81; 95% CI, 0.79-0.82), breast cancer (16%), lung cancer (13%), colorectal cancer (12%), congestive heart failure (CHF) (5%), venous thromboembolism (3%), atrial fibrillation (4%), acute myocardial infarction (11%), and dementia (2%). For the use of estrogen and progestogen combo-therapy, both E+ progestin and E+ progesterone were associated with increased risk of breast cancer by 10%-19%, but such risk can be mitigated using low dose of transdermal or vaginal E+ progestin. Moreover, E+ progestin exhibited significant risk reductions in endometrial cancer (45% or adjusted hazards ratio, 0.55; 95% CI, 0.50-0.60), ovarian cancer (21%), ischemic heart disease (5%), CHF (5%), and venous thromboembolism (5%), whereas E+ progesterone exhibited risk reduction only in CHF (4%).

Conclusions

Among senior Medicare women, the implications of menopausal hormone therapy use beyond age 65 years vary by types, routes, and strengths. In general, risk reductions appear to be greater with low rather than medium or high doses, vaginal or transdermal rather than oral preparations, and with E2 rather than conjugated estrogen.

Topics

Related research

Therapeutics › Hormonal Agents › Estrogen Preparations · General Gynecology › General Health › Cardiovascular Health · Perimenopause and Menopause › Hormone Therapy › Benefits and Risks
Seo H Baik, Fitsum Baye, Clement J McDonald
S Baik, F Baye, C McDonald
PMID 38595196 38595196 DOI 10.1097/GME.0000000000002335 10.1097/GME.0000000000002335 Baik et al. 2024, Baik 2024